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Summary Five samples of tonsil, 10 reactive lymph nodes and 65 consecutive cases of non-Hodgkin
lymphoma (NHL) were evaluated in suspension phenotyping with the monoclonal antibodies aLeu-I, aLeu-2a,
aLeu-3a, OKT1, OKT3, OKT4, OKT6, OKT8, W6/32, 26/114, DA-2, 2DI, J5, AN51 and OKT9 together with
conventional surface marking by rosetting (E, Fcy, Fcts, C3b, C3d) and staining for surface and cytoplasmic
immunoglobulin (Slg, CyIg) heavy and light chain classes. The results confirm the reproductability and
specificity of staining with monoclonal antibodies against T cells and T cells subsets. Evidence is presented for
reactivity of aLeu-I antibody with SIg positive and Ia positive cells in some lymphomas (centroblastic
centrocytic, lymphocytic and immunoblastic), and 2 cases showed evidence of marking with OKT3 on SIg
positive cells in T cell predominant immunoblastic lymphoma. Lymphoblastic lymphomas of T cell type
expressed the marker OKT6. On the basis of these results criteria for the diagnosis of T cell lymphoma are
suggested. The monoclonal antibody J5, reactive with C-ALL antigen, showed variable positivity, occasionally
strong in B cells in cases of centroblastic and centrocytic follicular lymphoma. Proportions of cells staining
with the monoclonal antibody OKT9 showed a correlation between levels of cellular expression of transferrin
(trf) receptor and the histological grade of malignancy, OKT9' cells being elevated in high grade lymphomas,
and in some cases of transforming lymphoma of low grade histological class. These results are discussed and
indicate the advantage of employing a wide range of defined monoclonal reagents in the phenotypic
evaluation of NHL.
Previous reports on phenotyping in non Hodgkin's
lymphoma (NHL) indicate marked heterogeneity
within tumours of similar appearance and
histological class. Nevertheless such studies have
shown broad correlation between histological class
and phenotype (Jaffe et al., 1974; Gajl-Peczalska et
al., 1975; Stein, 1976; Stathopoulos et al., 1977;
Brouet, et al., 1977; Jaffe et al., 1977; Lukes et al.,
1978; Stein et al., 1979; Habeshaw et al., 1979;
Janossy et al., 1980; Aisenberg, 1981), although it is
not yet clear what contribution more precise
immunological diagnosis can make to the
management of this disease (Bloomfield et al., 1979;
Strauchan et al., 1978).
A significant effect of these studies has been to
focus attention on the cellular origin, differentiation
and possible pathogenic role of the cell populations
within the lesions. This applies particularly to the T
cell populations accompanying B lymphocytic
neoplasia of follicular and immunoblastic types
(Habeshaw et al., 1979; Janossy et al., 1980), which
until recently were evaluable only on the basis of E
rosette formation, or reactivity with heteroantisera
of pan T cell or limited T cell subset specificity
(Evans et al., 1978). With the availability of
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monoclonal antibodies, it is now possible to
accurately quantify functionally correlated T cell
subsets (Reinherz et al., 1980b) within the lesions in
both suspensions and frozen sections. Since many of
these reagents are currently available commercially,
we have attempted to evaluate their utility in
phenotyping normal and neoplastic lymphoid
tissues.
In this paper we report the results of a
phenotypic analysis of 10 reactive lymph nodes and
65 consecutive cases of NHL studied with a range
of monoclonal antibodies of pan T cell and T cell
subset specificity, other monoclonals of defined
specificity for lymphoid cell surface antigens, and
"(conventional" surface phenotyping of surface
immunoglobulin bearing cells (SIg), cytoplasmic
immunoglobulin bearing cells (CyIg), E rosetting
cells and Fcy, Fc,u, C3b and C3d rosetting cells in
the same samples.
The investigation aimed to (a) assess the
specificity, reproducability and immunodiagnostic
utility of a number of comparable T cell-specific
monoclonals; (b) explore the nature of the T cell
components found in association with B cells in the
T cell-predominant phase of lymphomas of
follicular and of immunoblastic subtypes; (c)
establish phenotypic criteria to distinguish T cell-
predominant B cell lymphomas from true
© The Macmillan Press Ltd., 1983.328 J.A. HABESHAW et al.
lymphomas of mature T lineage cells and (d)
characterise cells previously described in tumours as
"null" or "receptor silent" with "conventional"
modes of surface phenotyping.
Patients
Patients attended the Medical Oncology Unit, St.
Bartholomew's Hospital, from January 1981 to
December 1981. (Adult patients were under the care
of Dr T.A. Lister, and children under that of
Professor J.S. Malpas).
Materials and methods
Lymph nodes and tissues: cell suspensions
Single cell suspensions from lymph node biopsies
were prepared in tissue culture medium RPMI 1640
within 20min of surgical removal. Peripheral blood
and splenic lymphocytes were prepared by
centrifugation on Lymphoprep (Nygaard) at 400g
for 25min at 200C. Pleural aspirates were diluted
with tissue culture medium RPMI 1640 containing
heparin (10 unitsml-1) and the cells recovered after
washing and centrifugation. Cell counts were
adjusted to give a concentration of 5x 106
nucleated cells ml-1 and viability was assessed by
trypan blue dye exclusion.
Preparation ofred cells
Sensitised red cells for assessment of Fcy, Fc/u, C3d
receptors were prepared as previously described
(Habeshaw et al., 1979). C3b-sensitised ox RBC
were prepared using R3 reagent incubated with
IGM-sensitised ox RBC for 75sec at 37°C,
followed by dilution and washing with ice-cold
veronal buffered saline at 0°C. Cells sensitised in
this manner are equivalent in their reactivity with
C3b receptor expressing cell lines as red cells
prepared with purified C components known to
express human C3b.
Preparation and use of antibodies for suspension
phenotyping
For the detection of surface Ig on untreated or
acetate washed lymphoid cells in suspension,
conventional, commercially available rabbit or goat
antisera, or FITC conjugates of IgG preparations,
were used. These included antisera against i, y, and
a heavy chains, K and A light chains (Nordic, Miles,
Dako, Behringwerke). Purified IgG fractions were
prepared from whole antiserum by ammonium
sulphate precipitation, DEAE sephadex
chromatography, or affinity chromatography on
staph protein A-Sepharose (Pharmacia). Two
preparations of anti-IgD antiserum were used, goat
anti-human IgD (courtesy of G. Janossy and S.
Mattingley, Royal Free Hospital) and sheep anti-
human IgD (Seward Laboratories). y-globulin
fractions prepared from these antisera were
absorbed against CNBR-sepharose coupled human
IgG and conjugated with FITC by the method of
Forni (1979) to give a final product containing
0.25mgml-1 antibody and F:P ratio of 2:1 to 4:1.
These antisera were diluted to 1:10-1:16, aliquoted
in 10ul quantities and used at a final dilution of
1:20. All antisera were deaggregated by
centrifugation (1O0,000g for 1 h) before use.
Monoclonal antibodies
The monoclonal antibodies (obtained from
commercial sources, or from other laboratories)
used in this study are given in the Appendix. They
were tested for reactivity against a range of normal
lymphocytes from tonsil, blood and lymph nodes,
and against CLL or ALL cells where appropriate.
Effective dilutions were established empirically for
these reagents, which were then aliquoted in 5jpl
quantities and stored as recommended by the
manufacturers (at +4°C or below -4°C). The
effective antibody concentrations used were from
100-250,gml-1 antibody protein and reagents at
this concentration were used at final dilutions of
1:15-1:25.
Binding of monoclonal antibodies was detected
using goat anti-mouse (GAM) Ig obtained by
affinity chromatography of whole goat anti-mouse
serum on mouse IgG columns. The retained and
eluted Ig was then passed through a column of
Sepharose coupled pooled human Ig (IgG and IgM)
to remove any cross-reactivity with human Ig. The
GAM IgG was coupled with fluorescein
isothiocyanate (Sigma) by the method of Forni
(1979) to give a product containing 0.38mgml-l
IgG, with an F:P ratio of 3:1. This preparation was
diluted 1:25, aliquoted in 5 ul quantities, and used
at a final dilution of 1:10. Control incubations
indicated no detectable reactivity with human
leukocyte preparations at the dilutions used.
Peanut lectin staining
FITC-conjugated PNA was prepared according to
the method described in Rose et al. (1980).
Phenotypic analysis
The methods of quantitating E rosettes, Fcy, Fc,u,
C3b and C3d rosettes, SIg and CyIg staining were
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Peanut lectin binding was assessed by the method
of Rose et al. (1981). Staining with monoclonal
antibodies was detected by a sandwich technique as
follows: The concentration of the cell suspension
was adjusted to give 1 x 107 cells ml-'. Fifty-pl of
cell suspension was added to a 500,ul polypropylene
tube containing 5p1l of the appropriate monoclonal
antibody, mixed and incubated for 30min at 4°C.
The cell suspension was washed x 2 in PBS and the
supernatant aspirated completely from the cell
pellet. The appropriate FITC-conjugated GAM-IgG
in 5,pl aliquots was diluted to 25,ul in PBS, and
added to the cell pellet. Cells were resuspended and
incubated for a further 0.5-1 h at 4°C. The stained
cells were then washed twice in PBS, pelleted and
resuspended in lOp10 PBS. Wet preparations were
made, the coverslips sealed with wax and counted
using the Zeiss photomicroscope IV equipped for
incident illumination (for fluorescence) and phase
contrast microscopy. Viable nucleated cells showing
distinct positive fluorescence only were counted.
Control preparations included suspensions stained
with inappropriate monoclonal antibody (e.g. anti-
platelet antibody AN51 (see Appendix) or mouse
ascites fluid (negative controls). Staining with
monoclonal W6/32 (antimonomorphic HLA, A, B,
C) and 26/114 (MasO18b Seralab) (anti-fl2M) were
used as positive controls.
Results
I Specificity and reproducability of monoclonal
antibody reactions with normal and neoplastic tissues
The monoclonal antibodies against T cells and T
cell subsets gave equivalent results when tested
against suspensions of cells from normal tonsil
(Table I) and lymph nodes (Table II). There were no
significant differences in the proportions of T cells
determined by aLeu-I and OKT3 pan T cell
antibodies, or between the subset specific
monoclonals OKT4/ocLeu-3a and OKT8/cLeu-2a.
The T cell subset ratios with these pairs of
antibodies were not significantly different.
The anatomical distribution of the T cell subsets
defined by these monoclonals and B cell types
defined by conventional antisera and HLA-Dr
specific monoclonals are given in Table III and in
Figure la-d for normal lymph node tissues.
Table I Phenotype analysis of tonsil suspensions with the monoclonal antibody panel
E rosette OKT1 OKT4 OKT6 OKT8 aleu-I caLeu-2a aIeu-3a DA-2 SIg C3d PNA
30 42.3 29.5 0 9 38.75 9.75 26.25 50.75 48 45 21.75
(11-42) (37-50) (22-37) (0) (6-12) (35-46) (6-12) (22-35) (48-54) (41-62) (28-60) (10-29)
Subset ratio OKT/OKT8 = 3.30 aLeu-3a/aLeu-2a = 2.69.
(Mean % values and range in parenthesis for 5 samples are given.)
Table II Phenotype analysis of reactive lymph node suspensions by the monoclonal antibody panel,
rosette formation, and functional assays
Pan Tcell markers Tsubset markers Subset ratios Other markers
E rosettes 42.2+2.1 OKT4 30.9+6.5 T4/T8 2.13 SIg+ 35.2+5.0
(36-55) (12-54) (0.9-4.2) (18-76)
aLeu-I 58.8+6.0 aLeu-3a 28.0+6.0 xLeu-3a/ 2.15 DA-2 30.56+4.5
(41-69) (11-61) acLeu-2a (0.7-5.8) (HLA-DR) (18.51)
OKT3 58.0+5.2 OKT8 17.7+3.4 aLeu-2a/ 2.15 Phago- 8.27+ 1.9
(31-78) (9-30) OKT4 (0.7-4.5) cytes (1-18)
UCHTI 48.4+4.0 15.6+2.3 oLeu-3a 2.03 C3d 32.3+4.6
(37-56) aLeu-2a (6-21) OKT8 (0.7-4.7) rosettes (6-60)
T4+T8 48.7+5.1 C3b 11.2
(30-67) rosettes (1-20)
aLeu-3a 43.6+4.1 Fcy 6.8
xLeu-2a (27-72) rosettes (2-18)
(Values given are mean % of positive cells, +s.d., and range of values (in parenthesis)).
(data for W6/32, J5 and OKT6 not shown).
(data for Fc,u and PNA not shown).330 J.A. HABESHAW et al.
Table III Location and phenotype of the principle cellular populations of reactive lymphoid tissue
assessed on suspensions and frozen sections
Cell type Location Phenotype
T helper/inducer Interfollicular area+ (E+)T4+ Leu3a+, T1
germinal centre (sub UCHTI+, T3+
coronal)
T suppressor/cytotoxic T cells and interfollicular Ti+ T3+ UCHTI+ Leu-2a+
zones
B cell of lymphocyte Lymphocytic mantle of corona SIgM+D+, C3d+
mantle DA-2 (HLA-Dr+) PNA-
B cell of PNA+ type Germinal centre SIgG or A+, C3d+
DA-2 (HLA-Dr+) PNA+
B cell of PNA- type Germinal centre SIgM+, C3d+
DA-2 (HLA-Dr+) PNA-
Tingible body macrophage Germinal centre OKT4+ DA-2+ C3b+ Fcy+
Dendritic reticulum cell Germinal centre DA-2+ (Fcy+). IgG and
IgM in section.
Interdigitating
reticulum cell T cell areas DA-2 (HLA-Dr+)
Sinusoidal macrophages Sinuses DA-2+ (weakly)
Fcy+ C3b+
OKT8+ (in section)
OKT6+ (sometimes in section)
Figure la-d Normal distribution of T and B subsets in reactive nodes by immunoperoxidase staining.
Figure la Reactive follicle showing characteristic "margination" of Leu3a + T helper cells to the interface
between the corona and germinal centre proper. Primary antibody antibody Leu-3a. Second antibody
affinity-purified HRP-labelled goat anti-mouse IgG. x 60.CELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS
Figure lb T cell area showing marked positivity for HLA-DR in the interdigitating reticulum cells. Primary
antibody DA/2. Second antibody affinity-purified HRP-labelled goat anti-mouse IgG x 60. iMy~~'4
$if. 4~~~~~~~~~~~ ;'~~~~~~.. ~~~~~~f W
Figure Ic T cell area showing cellular specificity of staining with the monoclonal antibody OKT3. Primary
antibody OKT3. Second antibody affinity-purified HRP-labelled goat anti-mouse IgG x 60.
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Figure Id The distribution of IgD+ cells in the coronal zone of normal germinal follicle. Primary antibody
goat x human IgD. Second antibody HRP-labelled F(ab)2 rabbit anti-goat IgG x 60.
Figure le The retention of coronal localization of IgD positivity in follicular lymphoma (case PA, Table
VIII). Primary antibody goat anti-human IgD. Second antibody HRP-labelled F(ab)2 rabbit anti-goat Ig x 60.CELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS
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Figure If Patient A.S. C-ALL antigen distribution staining with J5 monoclonal clearly limited to the
neoplastic follicle. This appearance is typical of follicular lymphoma, and is not seen in normal (reactive)
germinal centres. Primary antibody J5 monoclonal against C-ALL antigen. Second antibody HRP-labelled
affinity-purified goat anti-mouse IgG x 60.
II General analysis of the cellular composition of
selected classes ofmalignant lymphoma
The subset specificity of the monoclonal anti-T cell
antibodies was likewise assessed on 7 cases of
centroblastic centrocytic follicular lymphoma (Table
IV), 7 of immunoblastic lymphoma (Table V) and 5
of malignant lymphoma of lymphocytic type (Table
VI). Discrepancies between the reactivity of the pan
T cell antibodies aLeu-I and OKT3 were observed
in all instances, showing that aLeu-I antibody
-detects an additional subset of cells expressing the
65K MW glycoprotein antigen, which is not
represented in the T cell subset as defined by the
OKT3/UCHT-I monoclonals, the sum of OKT4
and OKT8 positive cells, or the E+ populations.
These conclusions are compatible with published
data on peripheral T cell subsets in man (Reinherz
et al., 1979a, b, 1980b; Janossy et al., 1980;
Poppema et al., 1981).
In view of these data, T cell subset-specific
monoclonals OKTl/aLeu-I, OKT3/UCHT-I, and
the T cell marker E rosettes, are expressed separately,
and T cell proportions assessed as defined below.
The total numbers of T cells in a given sample of
normal or malignant peripheral lymphoid tissue are
equivalent to the population defined by the pan T
cell monoclonals OKT3 and UCHT-I. The
cytotoxic/suppressor subset is defined as the (Leu-
2a+ OKT8+ OKT3+) population, and the
helper/inducer subset has the phenotype (OKT3+
OKT4+/Leu-3a+). In the examination of the
individual lymph nodes in cases of malignant
lymphoma (Section III below), the phenotypic
groupings used are (Leu-I+), (OKT3/UCHT-I+),
(OKT4/Leu-3a+) and (OKT8/Leu-2a+),
corresponding to total T cells (+non-T cells),
total T cells, T "helper/inducer" and T
"cytotoxic/suppressor" subclasses.
III Individual case analysis ofphenotype in NHL
The conclusions from the preliminary studies
(Results: section I), influenced the presentation and
interpretation of data in this section. The values for
xLeu-I are presented separately from the values of
OKT3 and UCHT-I positive cells. Since values
obtained for OKT4+ and Leu-3a+ cell populations
appeared identical, the mean values (OKT4+) plus
(Leu-3a+) for helper/inducer subsets are presented.
The mean values for (OKT8+) and (Leu-2a+) cells
similarly represent the proportions of
cytotoxic/suppressor T cell subsets. The
"helper/suppressor" ratio is presented as
OKT4+/OKT8+ cells. Data obtained with the
monoclonals W6/32 (anti-HLA ABC), 26/114 (anti-
fi2M) and 2DI (anti-HLeI) are shown or discussed
only where relevant. The monoclonal AN51 and
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Table IV Phenotypic analysis of 7 cases of centroblastic/centrocytic follicular lymphoma by the
monoclonal antibody panel and other cell surface markers
Pan Tcell markers Tsubset markers Subset ratios Other markers
E rosettes 17.1+4.9 OKT4 12.29+3.2 OKT4/OKT8 2.28 SIg+ 50.0+4.5
(6-42) (3-23) (0.2-5.8) B cells (31-72)
aLeu-I 30.0+0.8 aLeu-3a 14.4+3.1 acLeu-3a/ 3.26 HLA-DR+ 33.7+6.1
(27-32) (3-21) aLeu-2a cells (24-62)
0.43-6.33)
OKT3 24.9+2.5 OKT4 12.0+3.0 "Null" 12.9 +3.4
(14-31) (4-29) cells (4-42)
UCHTI 18.5+3.3 cxLeu-3a 7.6+2.3 C3d 22.0+5.2
(11-26) (3-17) receptor (0-24)
OKT4+OKT8 25.7+2.5 C3b 7.6+3.4
(19-35) receptor (1-10)
aLeu-2a 19.6+3.5 Fcy 7.6+4.4
+ (10-29) receptor (1-10)
cxLeu-3a PNA 29.4+7.3
(1-50)
J5+ 7.0+4.0
cells (0-16)
Values are included for Null cells, and for J5 positive cells.
(data for W6/32 and OKT6 not shown).
Table V Phenotypic analysis of lymph node suspensions from 7 cases of
lymphoma by the monoclonal antibody panel and the other cell surface markers
immunoblastic malignant
Pan Tcell markers Tsubset markers Subset ratios Other markers
E rosettes 38.8 +7.6 OKT4 24.0+10.4 OKT4/OKT8 1.38 SIg+ B cells 32.3+8.4
(14-73) (2-61) (0.3-4.36) (3.72)
aLeu-I 63.8+ 15.5 aLeu-3a 22.6+8.6 aLeu-3a/ 1.80 HLA-Dr cells 31.5+9.5
(10-91) (3-49) aLeu-2a (DA-2) (3-58)
(0.38 +4.45)
OKT3 52.0+ 13.4 OKT8 18.7 +7.4 Null cells 11.4+6.2
(18-92) (2-48) (0-42)
UCHTI (2 values only) aLeu-2a 13.6+ 3.1 C3d receptor 11.4+5.2
(8, 70) (8-22) (1-38)
OKT4+ 42.7+11.8 C3b receptor 2.4+0.9
OKT8 ( 4-75) (0-6)
aLeu-2a+ 36.0+9.6 Fcy receptor 7.9+4.8
xLeu-3a (11-60) (1-30)
Fcp receptor 2.5+ 1.4
(0-1 1)
PNA 21.4+6.1
(8-55)
(data for W6/32, J5 and OKT6 not shown).
The values given are the mean % of cells positive for each marker +s.d., and range of values (in
parenthesis).CELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS
Table VI Phenotype analysis of lymph node suspensions from 5 cases of malignant lymphoma of
lymphocytic type by the monoclonal antibody panel and other cell surface markers
Pan Tcell markers Tsubset markers Subset ratios Other markers
E rosettes 31.3+15.6 OKT4 15.8+5.5 OKT4/OKT8 1.32 SIg+ B cells 35.4+ 13.1
( 3-70) (8-35) (0.5-4.38) (4-71)
aLeu-I 39.8 + 10.6 aLeu-3a 11.3 +5.3 acLeu-3a/ 1.32 HLA-DR+ cells 42.0+11.5
(25-73) (3-24) aLeu-2a (15-73)
OKT3 27.8+6.7 OKT8 16.0+4.7 (0.23-2.33) "Null" cells 33.4+ 12.4
(12-40) (5-28) (4-73)
OKT4 32.2+6.2 aLeu-2a 18.0+5.4 C3d receptor 29.8+10.7
OKT8 (13-43) (7-30) (1-56)
ocLeu-2a 29.3+6.7 C3b receptor 16.2 +7.5
+
aLeu-3a (10-41) (4-42)
Fcy receptor 19.0+ 11.8
(1-58)
Fcp receptor 15.2+9.7
( 1-57)
The values given are the mean % of cells positive for each marker,
parenthesis).
(data for W6/32, OKT6 and UCHTI (2 only) not shown)
Data for PNA (negative), J5 (negative) are excluded.
mouse ascitic fluid gave negative reactions in all the The 15 p;
presented cases. follicular lymp
The data in this section are presented according M.W., A.Br.,
to the histopathological diagnosis based on predominance
Lennert's modification of the Kiel classification. The OKT3+ UCI
largest group (tumours of follicular derivation) are the OKT4+
presented first. These include centroblastic presence in
malignant lymphoma (Table VII), centroblastic and double-marke
centrocytic follicular lymphoma (Table VIII) and expression oi
centrocytic lymphoma of small or large cell type populations.]
(Table IX). Tumours of follicular centre cell cases.
derivation are phenotypically classified as being of Patients P.
B cell origin, despite the sometimes high, and excess of Leu
occasionally predominant, populations of T cells by OKT3+ +
within the lesions. (OKT8+) cell
Two of the 5 cases of centroblastic lymphoma (I.C. T populatior
and C.B.) showed T cell predominance as assessed excess of cyto
by presence of(OKT3+ UCHT-I+ Leu-I+) T cells. T helper/indu
All cases showed light chain class restricted B cell In patients P.
populations of variable heavy chain isotype. Patient E-. In 7 pati
I.C. had, in addition, a population of light chain S.A., A.D.) th
class restricted plasma cells not expressing HLA- chain class r
DR antigen. Patients C.B. and J.S. showed suspension p1
significant populations of OKT9+ cells, which >5). The val
might reflect the comparatively large proportion of C3d receptor
proliferating cells in this class of tumour. PNA and follicular B c
C3d receptor expression do not appear to be PNA are exp
important markers of B cell populations in J.K.N.), and
centroblastic lymphoma. P.A., A.Br). I
+s.d. and the range of values (in
atients with centroblastic centrocytic
phoma (Table VIII) show patients A.B.,
IE.Z., J.K.N. and A.D. with T cell
e. In patients J.K.N., A.D., A.Br., the
HT-I+ cells were less than the sum of
OKT8+ populations, suggesting the
these lesions of OKT8+/OKT4+
d T cells, or alternatively, the
of OKT4+ on an additional non-T
Double staining was not done in these
A., M.W., M.E. and J.K.N. showed an
l-I+ cells over total T cells (as defined
UCHT-I+, and sum of (OKT4+) and
Is), suggesting axLeu-I presence on non-
ns. Patient D.C. showed a marked
)toxic/suppressor T cells (OKT8+) over
icer cells (OKT4+), T4/T8 ratio 0.07.
.A. and M.E. the T cell population was
ients (D.C., M.E., M.W., A.Br., J.K.N.,
e B cell population did not show light
restriction (by established criteria of
henotyping K:L ratio > 10, L:K ratio
lues obtained for PNA positivity and
expression show the heterogeneity of
xll subsets; in 6 cases both C3d and
pressed (A.S., R.N., M.W., E.B., A.M.,
in 3 cases neither is expressed (A.D.,
These markers are concordant in the
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Table VII Phenotype of lymph node suspensions from patients with
centroblastic lymphoma (MLCB)
E
Fcy
Fcp
C3b
C3d
G
M
A
D
K
PNA
DA-2
J5
ocLeu-I
OKT3/UCHTI
OKT4/aLeu-3a
OKT8/aLeu-2a
OKT9
OKT6
CyIg
T4/T8 ratio
Patient Age/Sex Histology
CB JS HT
50M 43/M 49/F
MLCB/PO MLCB MLCB
37 7 11
2 0 3
0 0 0
0 3 0
1 12 34
1 4 16
30
3
22
2
2
71
0
63
75
49
17
18
4
Neg
2.9
78
0
0
2
69
0
82
6
20
25
5
15
22
0
ND
0.3
60
4
4
3
65
0
70
0
14
15
7
6
8
0
Neg
1.1
MB
68/M
MLCB
20
10
0
11
10
2
60
4
0
50
3
3
46
0
6
8
4
7
6
0
Neg
0.57
IC
50/F
MLCB/PO
29
2
9
0
28
17
10
6
0
49
10
19
0
70
67
21
35
7
0
10%,K*
0.60
*CyIg positivity is only noted where > 10% of the cells in the lesion are
CyIg positive and light chain class restricted.
MLCB/PO=Malignant lymphoma, centroblastic; polymorphic subtype.
majority of follicular lymphomas. In 8/13 tested
cases the monoclonal J5 reacted with > 10% of
cells, and J5 staining was restricted to B cells in
suspension (an observation subsequently confirmed
by double staining and in frozen section). (Figure if)
Patient A.M., with a transforming lesion
(CBccF--CB/cc/D) showed low numbers of T
cells, but high OKT9 expression. Patients E.Z. and
A.D., also transforming, showed T cell
predominance, but low numbers of OKT9+ cells.
Thus the histological assessment of transformation
includes 2 different phenotypic entities, one of T cell
predominance, and one of B cell predominance with
increased expression of trf receptor.
Six cases of centrocytic lymphoma (Table IX)
showed a B cell predominant phenotype, with low
levels of total T cells. In patients A.C. and G.Co.,
Leu-I expressing cells were more frequent than total
T cells. All patients except G.C. showed monoclonal
B cell phenotype. Patient G.C. showed a "null" cell
phenotype with strong HLA-DR expression on
most cells. It is of interest that the B cells in theCELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS 337
Table VIII Phenotype oflymph node suspensions from patients with centroblastic and centrocytic lymphoma (CB/cc/F)
Patient Age/Sex
(T) (T) (Spi) (7)
AS PA DC RN ME MW EB ABR JP EZ MG AM JKN SA AD
23/F 52/M 47/M 56/F 44/F 47/M 57/F 56/F 33/F 64/F 58/M 69/F 35/F 51/F 62/M
Markers
E 23 1 12 27 4 38 8 65 69 51 2 1 54 59 18
Fcy 4 10 48 0 1 12 0 1 5 36 2 11 2 41 11
Fc,i 2 1 0 0 <1 0 0 2 1 4 0 2 0 5 0
C3b 24 6 0 0 6 ND 2 1 0 0 0 12 1 1 1
C3d 29 1 30 42 26 28 33 11 3 11 3 31 19 33 4
G 1 7 0 24 6 5 32 24 14 15 74 6 14 31 27
M 31 13 35 12 16 14 60 2 8 1 3 90 29 28 1
A 0 3 37 2 < 1 21 3 12 26 1 13 3 6 18 4
D 1 11 45 11 0 12 22 0 14 2 0 23 10 5 4
K 3 34 30 30 21 36 62 14 3 17 5 10 12 14 47
A 28 4 40 3 6 8 13 16 20 4 3 70 7 36 8
PNA 50 74 ND 21 0 26 56 4 ND 2 72 80 11 ND 0
J5 16 2 16 ND 6 12 30 3 14 5 27 34 12 0 ND
DA-2 26 24 ND 24 50 12 55 45 30 13 1 11 46 6 2
axLeu-I 31 31 28 27 49 71 21 58 42 ND 13 2 93 33 35
OKT3/UCHT-I 31 19 31 30 40 60 22 68 53 88 8 4 68 39 54
OKT4/ocLeu-3a 22 21 2 10 20 48 15 45 28 43 9 1 62 18 50
OKT8/acLeu-2a 10 4 29 9 10 12 6 50 22 12 5 3 16 17 16
OKT9 2 <1 ND ND 0 2 1 3 5 4 2 60 4 0 0
SIg class ML MD/K Pcl GK Pcl Pcl G/MD/K Pcl G,A,L GK G ML Pcl Pcl Pcl
OKT4/OKT8
ratio 2.2 5.3 0.07 1.1 2.0 4.0 2.5 0.92 1.27 3.6 1.8 0.3 4.13 1.1 3.1
(T)=centroblastic and centrocyclic follicular lymphoma "transforming".
(Spl)=phenotypic profile of involved spleen.
pleural effusion from patient W.McK do not reflect
the monoclonality of the lymph node population, or
the blood B cells. One patient (A.C.) showed 22%
OKT9+ cells, but in all other cases OKT9+ cells
were infrequent. Two of the centrocytic large cell
tumour patients, W.McK. and G.Co., had only IgM
heavy chain isotype expressed on the B cells. In the
patients with centrocytic tumours of small cell type,
heavy chain isotype expression was more mixed,
including G- and A-positive cells. Only one patient,
P.C., showed a significant proportion of IgD-
bearing cells, in contrast to the patients with
follicular lymphoma.
Immunoblastic lymphoma
Eleven patients with immunoblastic malignant
lymphoma had phenotypic profiles of involved
tissues (Table X). In patients G.S., J.P. and T.McG.
the histological appearances were those of "T cell"
immunoblastic lymphoma. In patient G.S., T cells
with Leu-I/OKT3+ phenotype were present in
excess of the T4+ and T8+ subclasses. In double-
staining reactions a small SIg+ population (1-2%)
was OKT3+. The profile of T.McG. was similar
with a marked overlap of OKT3, Leu-I and K chain
staining on the blast-transformed population. On
subsequent cloning and culture these cells lost
OKT3 positivity, reverting to G K positive B cells
in 5 weeks (Izaguirre, 1982). Patient J.P. showed a
strongly K chain-predominant B cell component in
the lesion.
Patients P.C. and J.M. showed an excess of oLeu-
I expressing cells over total T cells. In P.C. and
J.M. a clear overlap of this axLeu-I marker and SIg
positivity was seen. In patient J.M. 28% of cells
were J5+, the only immunoblastic lymphoma to
show this pattern. In patient J.E., aLeu-I was found
on a major SIg- population. Patients J.E. and J.M.
also showed some PNA positivity, more usually a
marker of follicular lymphoma.
Three patients showed substantial populations of
CyIg+ B cells, including the two T cell predominant
immunoblastic lymphomas of G.S. and T.McG. In
patient D.B., only K chain staining plasma
cells/plasmablasts were found, despite the presence338 J.A. HABESHAW et al.
Table IX Phenotype of lymph node suspensions from patients with centrocytic lymphoma
Patient Age/Sex Histology
AC WMcK(N)* WMcK(PE)* WMcK(B)* GC GCo DL PC
60/M 68/M 68/M 68/M 27/F 62/M M 55/M
MLccSc MLccLc LSCL MLccLc MLccLc MLccSc MLccSc
Markers
E 2 2 42 19 3 20 6 14
Fcy 0 <1 <1 1 2 1 0 ND
Fcp 0 <1 <1 <1 0 0 0 ND
C3b ND 3 ND <1 0 4 12 ND
C3d 8 6 ND <1 ND 42 3 ND
G 19 30 8 6 1 20 16 70
M 83 47 8 53 0 69 5 80
A 16 0 4 16 2 2 0 10
D 3 0 1 0 0 0 4 37
K 12 0 21 4 2 2 60 84
A 85 70 15 45 3 76 3 19
PNA 0 0 0 4 0 6 0 0
DA2 37 ND 3 76 46 71 47 29
J5 0 0 0 ND 0 0 0 0
xLeul 60 ND 66 10 4 40 ND 32
OKT3/UCHTI 4 ND 54 11 8 20 30 14
OKT4/aLeu-3a 1 ND 32 6 1 16 11 4
OKT8/acLeu-2a 4 ND 8 6 2 3 10 12
OKT9 22 0 0 4 1 0 0 0
OKT6 0 0 0 3 0 0 1 2
CyIg Neg Neg ND ND Neg Neg Neg Neg
T4/T8 ratio 0.25 4.0 1.0 0.5 5.3 1.1 0.3
*N=Node, PE=Pleural Effusion, B=Blood.
of both K- and A-staining B cells in the lymph node
suspension. Six patients clearly showed monoclonal
SmIg (P.C., G.C., J.M., E.H., A.L., T.McG.). In
patients D.B. and G.S., CyIg expression was of one
light chain class. Patient J.E. lacked SIg+ cells, and
patients J.P. and F.O'C. had large excesses of K
chain staining cells which were not nominally
monoclonal (as defined by K:A ratios).
A striking feature of these immunoblastic
lymphomas is the extent of OKT9 positivity found
in the neoplastic population: in 2 cases, D.B. and
E.H., the majority of cells present expressed trf
receptors.
In view of the data from surface phenotyping of
immunoblastic lymphoma and follicular lymphoma,
the status of the entity "T cell immunoblastic"
lymphoma is not clear. T cell predominance in a
monoclonal B cell tumour, in which the T cells
have undergone blast transformation, or in which a
B cell subset expresses acquired or dysfunctional
OKT3 markers, is superficially a "T" cell lymphoma
(at least on histological criteria). It is important to
recognise that although in immunoblastic
lymphoma the blast-transformed population marks
as "T" lymphoid, there may be phenotypic evidence
of an additional,
cell population.
non-transformed "monoclonal" B
Malignant lymphocytic lymphoma
The profiles of involved tissues of 10 patients with
malignant lymphocytic lymphoma, and CLL, are
given in Table XI. Patient J.B. was described as
having pro-lymphocytic variant of MLL, and on
histological grounds the lesion of E.B. showed some
features of T-CLL involving lymph node. Six
patients (F.B., G.J., L.O'D., J.C., J.B., J.N.) showed
major populations of Leu-I+ cells. In L.O'D. aLeu-I
was the only marker expressed. In patients J.C. and
G.J., aLeu-I and SIg only were expressed. Patient
J.B. had aLeu-I, expressed with HLA-DR (Leu-I+
SIg+ (? HLA-DR+). The profile of patient J.N. was
E+, aLeu-I+, HLA-DR+, but SIg-. The E+, Leu-
I+ cells in patient J.N. lacked the OKT3/UCHT-I
pan T cell markers, and also the OKT4/aLeu-3a,
OKT8/aLeu-2a subset markers, but was clearly
HLA-DR . Patient E.B. showed cells of similar
phenotype in the peripheral blood (not shown) but
there is no evidence of this population in lymph
node. One difficulty in phenotyping lymphomas of
this class is in the assessment of SIg positivity, byCELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS 339
Table X Phenotype of lymph node suspensions from patients with immunoblastic lymphoma
Patient Age/Sex Histology
DB PC GC GS JE JM JP EH AL FO'C TMcG
57/F 31/M 47/M 59/M 62/M 59/F 72/F 67/M 74/F 68/M 56/M
MLIB MLIB MLPHg MLIB(7) MLPHg MLIB MLIB(7) MLIB MLIB MLPHg MLIB(7)
Markers
E 25 13 56 36 42 31 18 10 5 25 0
Fcy 11 2 30 0 3 0 <1 1 46 0 ND
Fcp 0 11 <1 0 2 2 0 1 29 1 ND
C3b 1 ND 0 0 6 4 5 1 ND 0 ND
C3d 26 1 16 0 6 1 24 13 12 4 ND
G 20 58 32 0 0 2 ND 2 10 15 91
M 9 8 6 < 1 8 45 ND 81 38 4 0
A 3 5 0 0 0 9 ND <1 1 <1 <1
D 2 36 30 0 <1 3 ND 80 1 0 <1
K 27 48 30 < 1 4 51 23 73 90 33 93
A 12 4 <1 <1 1 1 4 1 2 6 2
PNA 1 0 8 6 38 85 ND 2 1 11 5
J5 0 ND ND 0 1 28 ND 0 0 0 ND
DA2 76 85 24 3 28 55 21 83 27 36 60
aLeuI 17 72 35 91 95 85 25 5 8 18 68
OKT3/UCHTI 25 18 62 92 45 64 29 16 2 36 70
OKT3/aLeu-2a 15 17 15 44 2 47 12 9 2 12 8
OKT8/aLeu-2a 18 10 48 18 5 11 24 9 1 15 0
OKT9 58 18 ND 2 19 5 6 51 42 11 5
OKT6 0 0 ND 0 0 <1 ND ND 0 0 0
CyIg 10%K+ Neg Neg 11%MK Neg Neg Neg Neg Neg Neg 30%GK
T4/T8 ratio 0.83 1.7 0.31 2.44 0.4 4.3 0.5 1.0 2.0 0.8 8.0
MLIB =Immunoblastic Malignant Lymphoma MLP(Hg)= Malignant lymphoma pleomorphic (High grade).
The suffix (T) denotes histological appearances of "T" immunoblastic lymphoma.
immunofluorescence, since SIg is only weakly
expressed, and only 5 patients (G.J., J.C., J.B., H.M.,
E.B.) were thought to show clearly monoclonal B
cell populations. Previous observations on the
expression of Fcy, Fc4u receptors (Patients J.B. and
E.H.) and C3b and C3d receptors (Patients G.J.,
E.H., J.N., F.B.) are confirmed here and
demonstrate the difference between cells of CLL
type and follicular centre B cells in expression of
these markers. "Null" cell populations were present
in patients E.H., H.M. and L.G. (defined as Non T;
SIg-, HLA-DR-populations) although some
cytoplasmic IgM K plasmacytoid cells were present
in patient H.M.
Tcell lymphoma in adults
Only comparatively recently have T cell lymphomas
been recognised by a combination of histological
and phenotypic criteria, and there are no
established rules for classifying lymphomas of T
cells phenotypically. In this paper, the following
phenotypic criteria are regarded as essential before
a lymphoma can be unambiguously described as
"T" cell:
1 Lymphoma of lymphoblastic histology with acid
phosphatase positivity and TdT positivity
composed predominantly of cells expressing 2 or
more antigenic markers of T lineage specificity.
Lesions fulfilling these criteria are classified as T
lymphoblastic lymphoma.
2 Lymphoma of immunoblastic or high grade
histology, with cytological features of T cells
(convoluted or cerebreform nuclei) lacking TdT
enzyme, composed predominantly of cells
expressing 2 or more antigenic markers of T
lineage specificity, showing predominance of a
single T cell subset, and with no evidence of B
lymphocyte light chain class restriction.
3 Lymphoma of low grade histology with
cytological features of T cells, lacking TdT
enzyme, expressing 2 or more antigenic markers
of T lineage specificity, showing predominance of
a single T cell subset, and with no evidence of B
lymphocyte light chain class restriction.
The antigenic markers of T lineage specificity
considered are E rosette (or OKT1la) positivity,
OKT3/UCHT-I, OKT4/aLeu-3a, OKT8/aLeu-2a340 J.A. HABESHAW et al.
Table XI Phenotype of lymph node suspensions from patients with malignant lymphoma of lymphocytic
type
Patient Age/Sex Histology
LG LG FB GJ LO'D JC JB EH HM JN EB
65/F 65/F 50/M 58/M 54/F 53/M 64/M 72/M 49/F 57/M 46/F
MLL(Node) MLL(Spleen) MLL MLL MLL MLL MLL MLL MLL MLL MLL
Markers
E 2 8 11 3 6 5 32 32 3 70 11
Fcy 1 15 2 8 9 34 58 23 1 0 <1
Fcp 6 7 8 16 3 0 16 57 12 0 <1
C3b 4 5 35 33 0 0 9 16 10 42 4
C3d 2 5 55 10 2 8 50 41 0 56 <1
G 32 7 37 31 3 5 38 9 10 0 5
M 10 2 3 17 0 23 71 2 13 3 0
A <1 2 4 5 1 1 0 <1 0 1 0
D 0 0 1 3 0 2 35 5 0 0 2
K 3 2 10 57 2 46 70 9 23 4 88
4 7 20 1 1 6 <1 11 <1 <1 0
PNA 0 ND 0 ND 0 ND 8 18 ND 1 0
DA2 5 7 56 17 2 8 46 15 24 73 67
J5 0 0 0 0 0 0 ND 0 0 0 ND
aLeul 20 37 60 85 56 46 61 25 ND 94 42
OKT3/UCHTI 8 25 10 10 8 12 34 39 11 12 40
OKT4/aiLeu-3a 8 3 7 4 5 11 13 13 8 8 32
OKT8/aLeu-2a 3 15 3 3 4 4 21 17 14 4 8
OKT9 0 2 0 0 0 <1 ND 0 2 2 4
OKT6 0 0 0 0 0 0 ND <1 0 ND ND
Cylg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
T4/T8 ratio 2.7 0.2 2.3 1.3 1.2 2.8 0.62 0.76 0.57 2.0 4.0
and OKT6 positivity (valid only for TdT positive
lymphomas); OKT-I and Leu-I positivity alone
cannot be regarded as T lineage specific, neither can
the OKT9 marker. The T helper/inducer-to-T
cytotoxic/suppressor ratio is not regarded as
sufficient criterion for the determination of T subset
predominance, since (a) double-marked (T4+ T8+)
T cell populations are known to exist, and (b) the
major T cell population may be OKT3/UCHT-I+,
but OKT4/Leu-3a- or OKT8/Leu-2a-. In such
instances the "helper/suppressor" ratio is probably
irrelevant.
It is also important to recognise that apparent
monoclonal (i.e. light chain class-restricted) B cell
populations can occur in tumours composed
predominantly of T cells, in which both major
subsets of T cells are present. In such cases, the
correct descriptive term applied to the phenotype is
"T cell predominant monoclonal B". Five cases of T
cell lymphoma in adults which fulfil these criteria
are given in Table XII. An additional case of "T"
lymphoma diagnosed on histology/cytology but not
fulfilling all these criteria is also shown here (Patient
R.E.).
The patients A.S., F.S., E.M., P.J., C.M. (Table
XII) with adult "T cell" lymphoma showed T cell
predominance in the affected tissues, of a single
defined T cell subset. In patient F.S., with classical
T zone lymphoma involving lymph node
paracortex, this T cell population was
phenotypically E+, Leu-I+, OKT3+ and essentially
OKT4/Leu-3a-, OKT8/Leu-2a-. In patient A.S.,
with Sezary cell leukaemia, the phenotype was EB
Leu-I+ OKT4+ OKT8+, with strong suggestion of
overlap of these markers on the affected population.
In patient C.M., with T cell PLL, the major
population was E+ Leu-I+ OKT3+ with a high
proportion of OKT9+ cells.
Patient E.M. had Sezary cell leukaemia
supervening in long-standing mycosis fungoides.
The lymph node showed E+, aLeu-I +, OKT3+,
UCHT-I+, OKT4+ andaLeu-3a+ tobethephenotype
of the major cell population. More cells were EB
and aLeu-I+ than marked with OKT3/UCHT-I or
OKT4. The node lesion was characterised as
mature T helper/inducer T cell lymphoma (E+ Leu-
I+ OKT3+ OKT4+). In blood a very similar T cell
phenotype was found, but here the majority of cells
were E
Patient P.J. had a high grade diffuse lymphoma
of angular rather than convoluted cells showing
moderate mitotic activity, with no other obvious
features of T cell disease histologically. There was
no involvement of skin. The phenotype of thisCELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS 341
Table XII Lymphomas classified as adult T cell lymphoma by phenotype criteria
Patient
Age/Sex
AS FS EM EM PJ RE RE RE CM
70/M 64/M 71/F 71/F 48/M 63/M 63/M 63M 31/F
(blood) (node) (node) (blood) (node) (node 1) (eff) (node 2) (blood)
Markers
E rosettes 51 75 71 9 10 3 81 ND 83
xLeu-I 64 78 91 96 98 23 61 18 57
OKT3/UCHT-I ND 83 58 96 92 47 87 11 61
OKT4/aLeu-3a 56 5 36 86 95 39 64 16 0
OKT8/aLeu-2a 56 1 3 <1 < 1 25 23 2 5
OKT9 ND ND 3 0 0 100* 0 100* 45
OKT6 ND 0 0 0 0 0 ND 0 0
DA2 8 <1 3 4 4 16 3 <1 2
SIg ND 10 11 3 5 15 3 8 8
Fcy 8 18 2 20 3 0 15 3 ND
Fcu < I 0 0 1 0 0 67 8 ND
C3b ND 7 0 49 ND < 1 52 10 ND
C3d 15 0 5 14 1 0 33 5 ND
Histology Sezary T zone Sezary Sezary ML.HgU T zone ML.HgU "T" PLL
cell cell cell
leukaemia leukaemia
*Weak staining.
T zone=T zone lymphoma.
ML.HgU =Malignant lymphoma, high grade, unclassified.
lesion was clearly Leu-I+, OKT3+, OKT4+ (mature
T helper/inducer cell type), with few E+ cells
detected. Patient R.E. had 2 lymph node biopsies, at
diagnosis and at relapse (R.E.2) after treatment. A
pleural effusion (R.E.eff) was believed on cytological
grounds to show malignant involvement. The
phenotypic features in this case do not indicate
dominance of a single subset of cells clearly
showing two T cell markers. In both node biopsies
the greater population is of null cell type (non-B
non-T).
All populations in patient R.E. expressed HLA-
ABC and were 2DI , suggesting a lymphoid or
haematopoetic origin for the neoplastic cells, and in
both node biopsies, OKT9 staining was detectable
on the entire lymphoid population. Although the
significance of this finding is obscure, it might
indicate similarity with previously described cases
where T cell markers were expressed (Kung et al.,
1981; Aisenberg & Wilkes, 1980).
Lymphoblastic lymphoma of Tcell or null cell type
The phenotype of ALL shows 3 major subclasses of
disease: T cell type, C-ALL type, and B cell type.
These sub-groups correspond histologically to the
lymphoblastic lymphomas of childhood, which on
morphological and cytochemical criteria can be
segregated into T lymphoblastic lymphoma,
unclassified lymphoblastic lymphoma (U) and
lymphoblastic lymphoma of "Burkitt" type (B
lymphoblastic lymphoma).
In the histological categories of T lymphoblastic
and U lymphoblastic lymphoma, previous studies
have indicated phenotypic similarities between the
lymphoma and the corresponding cytological type
of acute leukaemia; it is currently not clear whether
the acute leukaemias are separate entities, or
whether lymphoblastic lymphomas are variants of
ALL (Habeshaw, 1981; Coccia, 1977; Murphy,
1978). In table XIII the phenotypic data are
presented for one control thymus gland (C.W.), 6
cases of lymphoblastic lymphoma thought to be T
cell type on histological and cytological criteria
(patients J.P.C., K.F., A.N., S.B., J.P., J.C.) and 2
patients with lymphoblastic lymphoma of U cell
type (patients L.T., Y.K.). The phenotype of the
presenting lesion in patient L.T. (L.T.p) and of the
recurrence after chemotherapy (L.T.r) are shown.
The control thymus gland (from a 22-year old
female patient at thoracotomy) shows the majority
of cells are E+, aLeu-I+, OKT3/UCHT-I+,
OKT4/cxLeu-3a+ and OKT8/oc-2a+. The marker
OKT6 is also present on virtually all thymocytes.
Reactivity with the monoclonal W6/32 shows the
43K glycoprotein core structure of HLA-AB(C) is
not expressed by all thymocytes. HLA-DR is
present on only a small population of intrathymic342 J.A. HABESHAW et al.
Table XIII Phenotypes of involved tissue from patients with lymphoblastic lymphoma of T cell or unclassified type
Patient
Age/Sex
Histology
JW JPL JC AN KF JP SB LT LT YK
22/F 11/M 13/M 7/M 3/F 14/M 16/M 7/F 8/F I I/F
Hyperplasia Skin Node Node Node Node Node Primary Recurrence Node
(Control) TLB TLB TLB TLB TLB TLB Node MLLB (U) MLLB (U)
MLLB (U)
Markers
E 96 66 12 ND 63 48 2 0 4 20
Fcy ND 4 1 0 3 0 1 <1 0 1
Fcp ND 0 <1 0 <1 3 3 0 1 2
C3b ND 0 <1 0 0 1 0 0 0 0
C3d ND 5 0 0 4 0 1 0 < 1 14
SIg 0 6 11 12 8 5 0 0 3 7
aLeu-I 83 58 89 30 80 60 100 65 30 24
OKT3/UCHTI 90 86 19 ND ND 38 <1 ND 9 20
OKT4/antiLeu-3a 90 14 20 80 7 64 97 1 < 1 20
OKT8/antiLeu-2a 81 72 12 70 50 95 2 2 2 6
OKT9 ND 48 3 ND ND 4 10 ND 28 ND
OKT6 84 60 18 15 80 62 100 25 0 0
J5 1 0 1 <1 28 47 0 1 0 ++*
PNA 46 0 40 20 1 ND 0 0 0 3
HLA ABC 43 53 71 80 100 100 100 100 100 100
HLA DR 9 1 6 9 2 3 0 <1 0 +*
TdT + + + + + + + + + +
Key: *Determination made on frozen section of affected node.
TLB Lymphoblastic lymphoma showing convoluted nuclei and/or acid phosphatase positivity.
Control: thymus removed at thoracotomy; histologically normal.
MLLB (U): Lymphoblastic lymphoma of cells without nuclear convolutions or acid phosphatase positivity.
cells, and the monoclonal J5 is not expressed on
thymocytes. Almost half the thymocytes bind PNA,
a finding confirmed by frozen section analysis.
Thymocytes are also TdT+.
In patient K.F., the predominant phenotype is
E+, Leu-I+, OKT8/Leu-3a+, OKT6+, and HLA+.
(OKT4, HLA-DR- and PNA-). Although in this
case a J5+ population was also present (28%) it
appeared reciprocally related to the expression of
OKT6. Patient A.N. showed predominant
phenotype of OKT4/Leu-3a+ and OKT8/Leu-2a+
"double-marked" T cells, about half of which
expressed Leu-I antigen. HLA-ABC was not present
on 20% of cells, but it is of interest that the PNA
binding and OKT6+ population corresponds
(proportionally) to the HLA-ABC negative T cell
subset in this case. The 12% of SIg+ B cells found
were thought to represent residual lymph node cells,
and are not considered part of the neoplasm.
Patient S.B. showed a predominant population of
OKT6+, Leu-I+, OKT4/Leu-3a+ and HLA-ABC+
T cells: (E-, OKT3/UCHT-I-, OKT8/aLeu-2a-
and PNA ). Patient J.P. showed the presence of
HLA-ABC, OKT6 and OKT8/Leu-2a antigens on
virtually all cells. Only a subpopulation of cells
were OKT3/UCHT-I+, OKT4/cxLeu-3a+ and E+.
This patient showed substantial numbers of J5+
cells in the lesion, and the values obtained for J5
and otLeu-I indicate reciprocal expression of these 2
markers as in patient K.F. Patient J.P.L. showed a
predominant E+ Leu-I+ OKT3+ OKT8+
population, which also expressed OKT6. Only half
the cells expressed HLA-ABC. Peanut agglutinin
staining was not seen. Patient J.C. showed a major
Leu-I+ population. A minority of cells were
OKT6+, and roughly the same proportion,
OKT3+, OKT4+ and OKT8 . HLA was present
on only 71% of cells, and a significant proportion
were also PNA+.
These data indicate the existence of several
populations of intrathymic, or "early" T cells, which
do not correspond to T cell populations found in
other lymphomas, or in normal tissues, outside the
thymic microenvironment. Other markers (J5,
W6/32, PNA) reveal further heterogeneity within
apparently homogeneous T marked populations.
The patients L.T., Y.K. showed lesions which did
not have the cytological features of T lymphoblasticCELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS 343
lymphoma. In the first biopsy from patient L.T.
(L.T.p) the majority of cells expressed xLeu-I
antigen, with a small population expressing OKT6
(phenotype Leu-I+ HLA+, Leu-I+, HLA+ T6+). In
the second, post-relapse biopsy (L.T.r), no OKT6+
cells were detected, the phenotype being essentially
"null", with a minority of Leu-I+ cells present. The
lymph node in patient Y.K. showed a null profile
on conventional marking. On frozen section the
tumour cells were clearly J5+, and HLA-DR .
Most striking was the appearance, in the affected
nodes, of islands of residual lymphocytes clearly
negative for J5, but in which both mature T and B
cells could be identified.
The intrathymic cell marker OKT6 is important
for thymic cortical lymphocytes, with virtually no
expression on lymphocytes outside the thymus,
except in tissues involved with lymphoblastic
lymphoma of T cell type. The marker J5 usefully
identifies lymphoblast populations of C-ALL type,
but this marker is also expressed in some
centroblastic and centrocytic lymphomas, and can
be positive on a subset of cells in T lymphoblastic
lymphoma.
Lymphoblastic lymphoma ofB cell type
Lymphoblastic lymphomas of B cell type are B cell-
predominant, with few admixed T lymphocytes, and
clear evidence of light chain class restriction. The
phenotypic data presented for four such cases are
shown in Table XIV. One of the cases (J.C.)
expressed J5 antigen on the cells, and HLA-ABC
was present in all cases. B cell status was confirmed
by the concordance of HLA-DR+ and SIg+ cells in
all cases. In patient L.A. where 54% of cells
expressed only K chain, the HLA-DR expressing
population corresponded to the M K SIg+
population. Inpatient J.D., the Erosettingpopulation
exceeded the T cell population defined by the other
T cell markers.
Discussion
Monoclonal antibodies represent molecular probes
which allow the detection of a single kind of
antigenic structure upon the cell surface. The use of
these reagents to classify cell subpopulations
provides a practical means of defining the cellular
composition of malignant lymphoma. The findings
reported here, and previously published data on the
specificity of monoclonal reagents (Reinherz et al.,
1979a, b; 1980 ) and on the distribution of the
identified cell subsets in tissues (Janossy et al., 1980;
Poppema et al., 1981) support the contention that T
cell-specific monoclonal antibodies used in NHL
consistently and reproducably define cell subsets
Table XIV Phenotype of involved tissue from patients
with lymphoblastic lymphoma of B cell type (MLLB(B))
Patient Age/Sex Histology
JC RW JD LA
36/F 4/M 5/F 2/M
MLLB MLLB MLLB MLLB
Markers
E 4 3 48 6
Fcy 1 ND 5 0
Fcp 1 ND 24 0
C3b 0 0 8 0
C3d 8 <1 12 0
G 12 0 84 2
M 75 69 14 36
A 14 0 10 0
D 6 0 16 0
K 77 16 68 91
A 2 78 5 0
PNA 10 4 ND ND
DA/2 20 77 46 72
J5 54 ND 0 ND
anti-Leul 14 3 28 8
OKT3/UCHLTI 15 3 16 10
OKT4/ocLeu-3a 8 3 22 3
OKT8/acLeu-2a 6 4 6 11
OKT9 14 10 0 ND
OKT6 2 0 0 ND
CyIg Neg Neg Neg Neg
T4/T8 ratio 1.3 0.8 3.7 0.3
which correspond closely to cells characterised
functionally and phenotypically in normal tissues.
Tcell specific monoclonals
The T cell specific monoclonals define several
"families" of T cell associated antigens. These are:
1 OKTI/aLeu-I 65K MW glycoprotein antigen
present on thymic and peripheral T cells, and
shared by SIg+ B cells in centroblastic and
centrocytic lymphoma (patient P.A. (Table VIII)),
centrocytic small cell lymphoma (patients P.C.
and G.C. (Table IX)); immunoblastic lymphoma
(patients J.B., J.N., F.B. (Table XII)). Leu-I+ B
cells do also occur as a normal lymphoid cell
subset (Caligaris-Cappio et al., 1982).
2 The OKT3/UCHT-I defined 19K MW
glycoprotein antigen found mainly on peripheral
T cell subsets, but which can occur separately
from either Leu-I or the "helper/suppressor"
subset antigens (see patients C.B. (Table VII),
R.N. (Table VIII), G.S. and J.E. (Table X)).
3 The OKT4/ocLeu-3a defined antigen found on T
cell subsets with helper/inducer activity which
occurs reciprocally with a second antigen344 J.A. HABESHAW et al.
OKT8/Leu-2a expressed by T cell subsets with
cytotoxic activity. Occasionally both antigens
may appear together on the same cell (patient
A.S. (Table XII)), particularly in thymus gland
(J.W. (Table XIV)) or in T lymphoblastic
lymphoma (Patient A.N. (Table XIV)).
4 The OKT8/aLeu-2a defined antigen confined to
cytotoxic/suppressor T cell populations, which
are found in thymus or T lymphoblastic
lymphoma, or as a constituent of reactive nodes.
No peripheral T cell malignancy of
suppressor/cytotoxic subclass was found in this
series, although reversed ratios of
"helper/inducer:cytotoxic/suppressor" T cells
were common in the described cases.
5 The receptor for sheep erythrocytes behaves as a
separate T cell specific marker, and is quite often
not represented on defined T cell populations of
either helper/inducer or cytotoxic/suppressor
subclasses (e.g. patients P.A., M.E., E.B. (Table
VIII)). The antigen detected by OKTI1 or
OKTlla monoclonals shows similar distribution
to the SRBC "receptor" (Verbi et al., 1982).
6 The thymic cortical antigen defined by OKT6,
present only in thymus gland or T lymphoblastic
lymphoma. Although never found on lymphoid
populations in reactive tissues, OKT6 expression
can occur on Langerhans cells in skin, and in the
sinuses of peripheral lymph nodes.
Since direct-coupled (FITC-or TRITC-labelled)
monoclonals were not available for this study it was
not practicable to test the simultaneous expression
of 2 different antigens on one cell, therefore the
existence of further heterogeneity of T cells in
lymphoma beyond that described here cannot be
excluded.
Other monoclonal reagents
M/32 The monoclonal antibodies W6/32 (anti
HLA-ABC) and DA-2 (anti HLA-DR) have
appreciable value for phenotyping in suspension.
W6/32 does not react with red cells, but reacts with
all nucleated cells, including plasma cells,
monocytes/macrophages, and epithelial cells. In
thymus, W6/32 negative cells occur, and the
presence of these cells bears an important
relationship to the expression of aLeu-I defined
antigen, OKT6-defined antigen and expression of
PNA binding.
DA-2 The monoclonal DA-2 against HLA-DR is
expressed by most B cells (but not by plasma cells)
and in frozen section is also found to be strongly
expressed by the inter-digitating reticulum cell of
the T cell areas. Other HLA-DR positive cell classes
include C-ALL antigen positive cells and blast
transformed T4/Leu-3a' T cells (Janossy et al.,
1977; Reinherz et al., 1979c).
J5 The J5 monoclonal, which detects the 95K C-
ALL antigen, is found to bind to some B cells in
lymphomas, particularly of the follicular CB/cc
subclass in suspension. J5 also reacted with a cell
sub-population in OKT6+ TdT+ T lymphoblastic
lymphoma. This C-ALL antigen expression at low
levels in T lymphoblastic lymphoma has previously
been noted using rabbit anti-ALL antibody
(Habeshaw, 1981) and is present in some T
lymphoblastic cell lines (Minowada et al., 1978;
Roberts et al., 1978; Greaves et al., 1981).
2DI The monoclonal antibody 2DI has proved
very useful in eliminating from the series "receptor
silent" tumours of uncertain histogenesis. All
lymphoid cell populations presented here were
defined by 2DI positivity confirming the validity of
this marker for "lymphoid" populations in general.
OKT9 expression in relation to histological class of
lymphoma
The monoclonal OKT9 did not act as a T
lymphocyte specific marker. On the other hand,
OKT9 expression was found to correlate with
histological class of lymphoma as shown in Table
XV.
It may be that the levels of OKT9 positivity
reflect the proliferative potential within any class of
lymphoma, since as shown here, the high grade
lymphomas tend to show higher levels of OKT9+
cells on average than low grade lymphoma (high
grade > 10, low grade <5). Since OKT9 detects the
trf receptor, then rapidly growing cells, with a high
metabolic demand for iron, may express receptors
for trf in proportion to their rate of proliferation
(Sutherland et al., 1981). It is of further interest that
a proportion of transforming B cell tumours express
increased OKT 9 positivity, while T cell
predominant transformation is not accompanied by
increased OKT9 positivity.
Phenotypic heterogeneity ofnull cells
All the null cell populations described express
HLA-ABC antigen and are found to be positive for
HLeI by the monoclonal 2DI. "Null" cell
populations occur frequently in lymphomas, and in
reactive lymph nodes. The cell type marking as
"null" has the phenotype HLA+ 2DI+ HLA-DR-,
and does not appear to express Fcy, Fcji, C3b or
C3d receptors. Lymphomas having significant null
populations of this type are centroblastic
centrocytic follicular (Patients A.S., P.A., R.N.
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Table XV Correlation of OKT9-positive cells in lymphoma
suspensions with histological grade of malignancy (excluding
phenotypically-defined adult T cell lymphoma)
Histologicc
OKT9+ cells
14
10
0
40
3
4
10
28
58
18
2
19
5
6
51
42
11
5
4
60
0
18
22
8
6
7
18
(0-60)
26 cases
xl high grade Histological low grade
Histology OKT9+ cells Histology
LB(B) 0 MLL
LB(B) 2 MLL
LB(B) 0 MLL
LB(T) 0 MLL
LB(T) 0 MLL
LB(T) 1 MLL
LB(T) 0 MLL
LB(U) 2 MLL
MLIB 2 MLL
MLIB 4 MLL
MLIB 0 MLL
MLIB 22 ML/cc/SC
MLIB 0 ML/cc/SC
MLIB
MLIB 4 ML/cc/LC
MLIB 1 ML/cc/LC
MLIB 0 ML/cc/LC
MLIB 0 ML/cc/SC
CB/cc/F (T) 0 ML/cc/SC
CB/cc/F (T) 2 CB/cc/F
CB/cc/F (T) 1 CB/cc/F
MLCB(P) 0 CB/cc/F
MLCB 2 CB/cc/F
MLCB 1 CB/cc/F
MLCB 3 CB/cc/F
MLCB(P) 5 CB/cc/F
2 CB/cc/F
4 CB/cc/F
0 CB/cc/F
Mean value 2 Mean value
Range (0-22) Range
28 cases
and H.M. (Table XII)) and "T zone" lymphoma
(patient R.E. (Table XIII)). Null populations were
not found in centrocytic lymphoma, centroblastic
lymphoma, or immunoblastic lymphoma. Previous
reports of "null" populations include E- T cells and
Leu-I+ SIg- HLA-DR+cells, which can only be
sub-classified using specific monoclonals. Failure to
find CyIg, the absence of HLA-DR, and the
apparent lack (or inconsistent expression) of Fcy
and C3b receptors suggest the null cell is neither a
plasma cell, nor a mononuclear phagocyte of
conventional type. It is thought unlikely to be of B
cell lineage, but could represent a subset of T
lineage cells, not detectable with current markers.
This is suggested from the existence of populations
bearing only the T cell specific marker.
In addition to the HLA-ABC+ 2DI+ HLA-DR-
"null" cell, other cells are found which express only
one class specific marker (other than SIg), These
include the E+ cell with no expression of other T
cell markers (HLA+ 2DI+ E+) and (Leu-I+ HLA-
DR') phenotype. The former phenotype occurred
in immunoblastic lymphoma (J.P. (Table X)),
centroblastic lymphoma (M.B. (Table VII)) and
lymphoblastic lymphoma (J.D. (Table XV)). Leu-I+
cells of the phenotypes (HLA-ABC+ 2DI+ Leu-I+
SIg+ and/or HLA-DR+) were present in
centroblastic and centrocytic follicular lymphoma
(P.A. (Table VIII)), centrocytic lymphoma of small
cell type (patients P.C., J.E., J.M. (Table X)) and
lymphocytic lymphoma (Patients J.B., J.N. and F.B.
(Table XII)).
Phenotypic heterogeneity in peripheral Tcells
There is evidence from this series that the antigens
detected by the monoclonals aLeu-I (OKTI),
OKT6, OKT3/UCHT-I, OKT4/axLeu-3a or
OKT8/aLeu-2a, and E rosette formation provide a
number of separate T cell phenotypes dependent346 J.A. HABESHAW et al.
upon the independent expression of these antigens.
Thus, although, peripheral T cells are normally E+,
OKT3/UCHT-I+, OKT4/Leu-3a+ or OKT8/Leu-
2a+, independent expression of these markers does
occur, giving rise to E-, OKT3/UCHT-I+,
OKT4/Leu-3a-, OKT8/Leu-2a- phenotypes within
the cell series classified as "T". It was found that the
T subset specific markers OKT4/aLeu-3a,
OKT8/ocLeu-2a never occurred without expression
of OKT3/UCHT-I and/or Leu-I. There is no
evidence that expression of OKT3/UCHT-I antigen
or Leu-I antigen is dependent on OKT4/Leu-3a,
OKT8/Leu-2a antigen expression. E- T cell
populations are common (E- OKT3/UCHT-I+),
occurring with both OKT4/Leu-3a positive and
OKT8/Leu-2a+ subclass specific markers. The
monoclonal antibody OKT1la, which detects the
sheep erythrocyte receptor (Verbi et al., 1982) was
not used in this series; the results obtained with E
rosetting would also apply to this antibody. E- T
cell populations were found in centroblastic
lymphoma (patients I.C., J.S., C.B. (Table VII)), in
centroblastic/centrocytic follicular lymphoma
(patients P.A., D.C., M.E., E.B. (Table VIII)) and in
patients with T cell lymphoma (E.M. (blood) and
P.J. (Table XIII)). In a number of other cases E
rosette levels were somewhat below total T cell
levels determined by pan T cell markers (e.g. patient
D.L. (Table IX)), probably due to the inherent
variability of the rosette technique.
In 4 cases (Patient C.B., (Table 7), R.N. (Table
VIII), G.S. and J.E. (Table X)) a significant
proportion of the total T cells expressed the pan T
cell markers ocLeu-I and/or OKT3/UCHT-I only. In
these patients total T "helper" and "suppressor" T
cells did not equal total T cells. The differences
encountered were not great, but do suggest the
presence of an undefined peripheral T cell with
phenotype Leu-I+ OKT3/UCHT-I+ (E+),
unreactive with OKT4/aLeu-3a or OKT8/aLeu-2a
antibodies.
"Double marked" OKT4+ OKT8+ T cell
populations have been described (e.g. in
prolymphocytic leukaemia) and also occur in
thymus gland (Greaves et al., 1981). In this series,
only one case (A.B. (CB/cc/F Table VIII)) showed
clearly a double-marked T cell population.
Phenotypic heterogeneity ofintrathymic Tcell subsets
It is believed that the phenotypes described of T cell
precursors and T cells of normal thymus gland, are
analogous to those of lymphoblastic leukaemia of T
cell type (Bhan et al., 1980; Greaves et al., 1981).
In lymphoblastic lymphoma, homogeneous
populations can be found (e.g. patient S.B. (Table
XIV) Leu-I+, OKT6+, OKT4+, HLA+, PNL-) but
in other cases the tumour cell populations all
represent mixtures of cells of different phenotypes
with variable levels of expression of the T cell
markers. The markers acLeu-I OKT6, W6/32 (HLA-
ABC), J5 and PNA are of further interest in this
class of lymphoma, since there appears to be
reciprocal expression of some phenotypic features
(e.g. HLA-ABC and PNA) in normal thymus gland
and in lymphoblastic lymphoma. In patient L.T.p,
the neoplasm contains apparently two populations:
Leu-I+, HLA-ABC+, OKT6- cells (65%) and Leu-
I , HLA-ABC+, OKT6' cells (25%). In patient
A.N., a presumptive population of Leu-I+ OKT6+
and PNA+ (15-30%) cells was HLA-ABC-. In
patient K.F., Leu-I+ OKT6+ HLA+ cells
accompanied a J5+, HLA-ABC+ HLA-DR-
population. These data suggest that there is an
important relationship between the antigens defined
by aLeu-I, OKT6, HLA-ABC and J5 in intrathymic
differentiation.
The experience with monoclonal antibodies
against defined T cell subsets in T ALL and in T
LBL illustrates clearly that several variations in
expression of related antigens (e.g. HLA-ABC and
OKT6 defined antigens) are possible within the
thymic microenvironment, and that lymphoblastic
lymphoma phenotypes are illustrative examples of
some of these variations. The total range of
phenotype within these classes of malignancy
obviously may be very great without necessarily
rejecting the hypothesis that the phenotype
expressed on the neoplastic population is equivalent
to the phenotype expressed on normal cells at an
equivalent stage of differentiation of maturation. In
particular, essential evidence of the normal
phenotype of intrathymic T cells in thymuses of
different chronological age is not available,
although it is known that "foetal" and "mature"
thymuses show different phenotypes.
In a recent paper, Bernard et al. (1981) reported a
series of 21 patients with lymphoblastic lymphoma,
and found phenotypic variants similar to those
described here. Commonly T lymphoblastic
lymphoma cells expressed T6 antigen with both
OKT4 and OKT8 expressed, together with the
thymocyte specific monoclonal OKT1O. Three
patients in their series expressed J5 reactivity, and 2
patients expressed both OKT3 and OKT6 antigens.
The monoclonal A50 (Boumsell et al., 1980) which
recognises an antigen present on peripheral T cells,
but absent from the majority of thymocytes showed
reciprocal expression in T all (A50+, 1/18 cases) and
lymphoblastic lymphoma (A50+, 10/21 cases).
Variations in expression of the HLA-ABC antigens
and PNA binding status were not reported. These
authors present evidence showing phenotypic
differences between lymphoblastic lymphoma and
T-ALL, and imply that lymphoblastic lymphoma
cells are later (i.e. more mature) variants of early T
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Phenotypic heterogeneity ofB cell subsets
In the absence of data for the available monoclonal
markers of B lymphocyte subsets, the most valid
marker for B cell subset heterogeneity remains the
expressed heavy chain isotype. The restriction of B
cells with expressed u+6 heavy chains (HC) to the
lymphocyte mantle or corona around germinal
centres is very striking, particularly in view of the
preservation of this distribution in follicular
lymphoma containing B cells of this phenotype
(Figure le). Moreover, lymphomas of B cells can
express either single or multiple HC isotypes on the
neoplastic population. In terms of HC class
expression, lymphomas of lymphoblastic B cell type
and centroblastic type are frequently of single IgM
HC class, while multiple HC isotype expression is
more frequent in follicular lymphomas. Lymphomas
of more "mature" B cells tend to express single H
chain isotype of IgG or IgA class. There is no
clearcut HC isotype relationship to histological
class.
A subset of B cells also expresses the antigen
defined by the aLeu-I monoclonal in 3 classes of
lymphoma: follicular, immunoblastic and
lymphocytic. Recent evidence that aLeu-I-like
antibody (RFA-I) identifies a mouse red blood cell-
positive SIg+ B cell subset in normal tonsil
(equivalent in phenotype to the CLL cell) implies
that a Leu-I bearing B cell may be a significant
component of B CLL, CB/cc/F lymphoma, and
some cases of immunoblastic lymphoma. This is of
interest, since a postulated bone marrow precursor
cell of the germinal centre B cell has not so far been
formally identified. If Leu-I+ B cells are (as
suggested by Caligaris-Cappio et al., 1982) of
peripheral origin and represent early "B memory"
cells, the germinal centre B cell precursor may well
prove to be a C-ALL+ SIg+ and HLA-DR+ B
lineage cell-a significant B cell component of most
follicular lymphomas. The presence of C-ALL
antigen has been previously shown on some cases
of B lymphoblastic lymphoma (Habeshaw, 1981),
and pre-B cells in C-ALL, and would suggest that
the lymphoblastic lymphoma of B cell type in
children, and CB/cc/F lymphoma in adults, may
be clearly related in their ontogenesis, despite the
contrasting histological appearances and clinical
behaviour.
With the means to describe accurately the T cell
populations in NHL, there is a temptation to
regard deviations of T cell phenotype from the
prescribed "T helper/inducer" or "T
cytotoxic/suppressor" subsets as evidence of
"neoplastic" transformation of T cells with or
without B cells in lymphoma. In our opinion there
is no evidence that unusual phenotypes (such as
OKT4/OKT8 double-marking T cell populations)
are necessarily "neoplastic" attributes of lymphoid
cells. Nor is there evidence from the phenotype to
suggest that proliferative B cell malignancies are
caused by unopposed "T helper" cell function or are
subject to ineffective "T suppression", as both types
of cell are usually present in normal proportions. In
normal or reactive nodes, the T cell component is
of both major subclasses, is arranged in a similar
distribution, and presumably has the same function
as the T cell component in, for example,
centroblastic and centrocytic follicular lymphoma.
The excess of OKT8/Leu-2a+ T cells over
OKT4/Leu-3a+ T cells commonly observed in this
series is also observed, though less commonly, in
reactive lymph nodes, but does not alone imply a
reaction by "cytotoxic" T cells against "neoplastic"
B cells. Moreover, there is good evidence that the
clonogenic components of NHL B cells are, like
normal B cells, dependent upon T cell factors, and
T cells, for growth (Izaguirre et al., 1980).
If abnormal (or "neoplastic") T cell phenotypes
are to be found, they would presumably be most
common in T cell lymphomas. Again, where this is
observed, T cell lymphomas appear to have quite
clearly developed attributes of T "helper" cells
(Kung et al., 1981), or phenotypes compatible with
origins from within thymus gland (Bernard et al.,
1981).
However, a proportion of high grade lymphomas,
histologically and cytologically defined as being of
"T cell" type, include light chain class restricted B
lymphoid components expressing surface and
cytoplasmic Ig. Similarly, B cell immunoblastic
lymphoma, of restricted L chain class, is often
accompanied by a major population of active, and
in some cases blast transformed HLA-DR+ T
lymphocytes in the lesion.
In this respect, previously published data
(Habeshaw et al., 1979) indicate that repeat biopsies
of T cell predominant lesions show T cell
predominance to be merely one phase in the
evolution of a dominant light chain class-restricted
B cell population with apparent malignant
potential. For understanding the nature of
lymphoma it is important to establish whether the
T cell predominance is associated with the normal
immunoregulatory mechanisms of T cells upon B
cells rather than concluding from the local
predominance of one cell class that the neoplasm
was essentially composed of "malignant" cells of
that type. For this reason the phenotypic criteria
adopted for defining a neoplasm as "T cell type" are
stringent, and emphasise the necessity of looking for
and excluding significant "monoclonal" B cell
populations in the affected tissues.
Suspension phenotyping shows that most NHL
are composed of mixtures of cells. These mixtures
include T cells of both major subsets, and B cells348 J.A. HABESHAW et al.
which may show heterogeneity of heavy chain
isotype, HLA-DR expression, markers such as
C3b/C3d receptor expression, or PNA binding.
Even T lymphoblastic lymphomas show some
evidence of being composed of mixtures of
phenotypically distinct subsets of cells, which may
mimic the normal patterns of phenotypic variation
occurring during intrathymic differentiation. The T
cell component in Hodgkin's Disease (Dorreen et
al., 1982) or in follicular lymphoma is often not
demonstrably abnormal in respect of the relative
proportions of T "helper" or "suppressor" cells, or
in their distribution as assessed by frozen section.
Nonetheless, mixtures of such cells do, in individual
patients, show the capacity for progressive growth,
ultimately with the emergence of a dominant B cell
population showing light chain class restriction, and
probably derived from a single B cell clone. From
these observations, it is proposed that T cell
populations in NHL of "B" cell type are an integral
part of the proliferative process, acting in the
selection and stimulation of the B cell component in
a manner analogous to the normal immune
response. The presence of a progressive, and
ultimately fatal, lymphoid proliferation represents a
rather gross disturbance of normal function which
is not always reflected in the cellular composition of
the neoplasm itself. This observation suggests that
the presence of a lymphoid neoplasm may be
symptomatic of a more widespread constitutional
disturbance of lymphoid homeostasis affecting the
immune system as a whole, rather than being the
expression of an intrinsic "malignant" attribute of a
single B cell clone. In view of the reported recent
success in the treatment of a lymphoma by
monoclonal anti-idiotypic antibody (Miller et al.,
1982), defective immunoregulation at this level
might well prove to be a major factor in the
pathogenesis of lymphoid neoplasia.
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Appendix
Monoclonal antibodies used in this study
Additional references are cited in some cases to
monoclonal reagents of apparently similar
specificity.
cxLeu-I Antibody defining glycoprotein 69-71K
antigen (P69-71) on normal T lymphocytes in
peripheral lymphoid tissue, a normal B cell subset
(Janossy personal communication), and SIg+ B cells
of CLL type (Wang et al., 1980). Similar antibodies
are clone P17 F12, IgG2a antibody identifying a
67K MW antigen of similar distribution (Engleman
et al., 1981), T65 reacting with a 65K MW antigen
(Royston et al., 1980) and clone A50, IgG2a
antibody, reactive with a T cell subset and CLL
cells (Boumsell et al., 1980).
acLeu-2a Clone SKI, an IgG antibody defining an
antigen complex of 2 or more disulphide bonded
subunits of 32K and 43K MW. Present on a subset
of T lymphocytes responsible for cell-mediated
lymphosis (suppress or/cytotoxic subset) (Ledbetter
et al., 1981).
aLeu-3a Clone SK3, an IgGI antibody defining a
55K MW antigen present upon T cells mediating
PWM-induced B cell antibody synthesis (Evans et
al., 1981).
OKT1 An IgGI antibody reacting with 70K MW
antigen expressed on all peripheral T cells and a
subpopulation of thymocytes (Reinherz et al.,
1979 ). P17/F12 and TIOI react with the same
antigen (Engleman & Levy, 1980).
OKT3 Monoclonal IgG2a antibody reacting with
a 19K MW antigen expressed on all peripheral T
cells, including both suppressor/cytotoxic and
helper/inducer subclasses (Kung et al., 1979).
OKT4 Monoclonal IgG2b antibody reactive with
a 62K MW antigen present on human T cells of
helper/inducer subclass (TH2 T cells) (Kung et al.,
1979; Reinherz et al., 1979a,b).
OKT6 Monoclonal IgG antibody reactive with a
49K MW antigen expressed only on thymocytes,
and absent from peripheral T cells (Reinherz et al.,
1980a). Similar monoclonal is Nal/34 (McMichael
et al., 1979).
OKT8 Monoclonal IgG2a antibody reactive with
an undefined antigen of peripheral T cells of
cytotoxic/suppressor subclass (TH2+) (Reinherz et
al., 1980b). A similar but not identical antibody is
OKT5 (Reinherz et al., 1980b).
W6/32 Monoclonal IgG2a antibody reactive with
the 43K glycoprotein "core" chain of HLA A, B, (C)
antigens (Parnham et al., 1979).
26/114 Monoclonal IgG2a antibody reactive with
the 12K MW protein /2 M (Trucco et al., 1979).CELLULAR ANALYSIS OF NON-HODGKIN LYMPHOMAS 349
DA-2 Monoclonal IgG2a antibody directed
against polymorphic p28/33 glycoprotein "core"
structure of HLA-DR determinants (Brodsky et al.,
1979).
2DI Monoclonal IgGI antibody directed against a
human haematopoietic cell antigen (HLeI) of 70K
MW, present on lymphoid and myeloid cells,
weakly expressed on granulocytes, monocytes and
early erythroid precursors. Absent from a wide
variety of tested epithelia (Beverly et al., 1980).
J5 Monoclonal mouse IgG2a antibody reactive
with the 95K antigen of C-ALL cells (Ritz et al.,
1980).
AN51 Monoclonal antibody reactive with human
platelet glycoprotein I. Unreactive with human
lymphoid cells (McMichael et al., 1981).
OKT9 Monoclonal antibody reactive with an 80K
dimeric antigen expressed on thymic T cell
(Reinherz et al., 1980a). It is now known to be
reactive with the cellular receptor for trf (Sutherland
et al., 1981) with widespread cellular distribution.
UCHT-I Monoclonal antibody reactive with 19K
MW antigen, expressed on peripheral T cells
showing identical reactivity to the monoclonal
OKT3 (Beverley P, personal communication).
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